Attention: Grabar Law Firm Investigates Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (AKRO)

Philadelphia, Pennsylvania–(Newsfile Corp. – August 2, 2024) – If you are a shareholder and have held shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) since before September 13, 2022 and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/contact Joshua Grabar at [email protected] or call 267-507-6085.

The Grabar law firm is investigating whether officers and directors of Akero Therapeutics breached their fiduciary duty to the company.

WHY: A recently filed securities fraud class action lawsuit alleges that Akero Therapeutics, through certain of its officers and directors, made false and/or misleading statements and/or failed to inform investors that (i) approximately 20% of patients enrolled in the SYMMETRY trial had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the patients with cryptogenic cirrhosis enrolled in the SYMMETRY trial did not have biopsy-proven compensated cirrhosis secondary to definitive NASH; (iii) the results of the patients with cryptogenic cirrhosis should not be considered in calculating the secondary endpoints of NASH resolution; (iv) Akero introduced a confounding factor into the design of the SYMMETRY trial that materially impacts the potential results of the trial and increases the risk that the trial will miss its primary endpoint; (v) the SYMMETRY trial did not comply with U.S. Food & Drug Administration guidelines for testing a drug to treat NASH cirrhosis because Akero did not rule out possible causes of cirrhosis other than NASH in any of the patients; and (vi) as a result, Akero materially misrepresented the nature of the SYMMETRY trial, its utility in supporting a New Drug Application, the likelihood of success of the SYMMETRY trial as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhosis.

WHAT YOU CAN DO: Current Akero shareholders who have held Akero shares since September 13, 2022 or earlier may request corporate reforms, repayment to the Company of funds spent on litigation defense, and court-approved award payments, all at no cost to them.

If you would like to learn more about this topic, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/contact Joshua Grabar at [email protected] or call 267-507-6085.

Disclaimer for Attorney Advertising

Contact:
Joshua H. Grabar, Esq.
Grabar Law Firm
A Liberty Square
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Phone: 267-507-6085
Email: [email protected]

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/218717